Kocaeli Med J. 2017; 6(3): 65-70

Prognostic Significance of The Neutrophil-to-Lymphocyte Ratio in Metastatic Pancreatic Cancer

Serkan Nebi Demirci, Gökmen Umut Erdem
Ankara Numune Training and Research Hospital, Department of Medical Oncology, Ankara, Turkey

INTRODUCTION: In numerous types of malignancy it is reported that high neutrophil-to-lymphocyte ratio (NLR) is associated with poor outcomes. We aimed to investigate the prognostic significance of NLR in patients with metastatic pancreatic cancer in our study.
METHODS: Between January 2013 and December 2014, 40 patients with metastatic pancreas carcinoma were retrospectively reviewed. The association of NLR with progression-free survival (PFS) and overall survival (OS) was analyzed using the Kaplan–Meier method.
RESULTS: Forty patients were included in this study. The median age of patients was 58.5 years (range 44–80 years) and the majority of patients were male (75.0%). High NLR (≥3.45) were obtained in 21 patients. NLR was a significant prognostic factor for both OS and PFS. The median OS for patients with high and normal NLR was 2.8 and 11.1 months, respectively (p <0.001). The median PFS for patients with high and normal NLR was 1.6 and 7.9 months, respectively (p <0.001). At the same time, PFS was significantly longer in male patients and those with a pancreatic head-located tumor.
DISCUSSION AND CONCLUSION: High NLR is a predictor of shorter OS and PFS in patients with metastatic pancreatic cancer. These results should be confirmed by prospective studies and multivariate analyses including more patients and other prognostic factors.

Keywords: Pancreatic cancer, neutrophil/lymphocyte ratio, prognosis

---

Metastatik Pankreas Kanserinde Nötrofil/Lenfosit Oranýnýn Prognostik Önemi

Serkan Nebi Demirci, Gökmen Umut Erdem
Ankara Numune Eðitim ve Araþtýrma Hastanesi, Týbbi Onkoloji Kliniði, Ankara, Türkiye

GÝRÝÞ ve AMAÇ: Çeþitli kanser tiplerinde yüksek nötrofil-lenfosit oranýnýn (NLO) kötü saðkalým sonuçlarý ile iliþkili olduðu bildirilmektedir. Çalýþmamýzda metastatik pankreas kanserli hastalarda NLO’nun prognostik önemini deðerlendirmeyi amaçladýk.
YÖNTEM ve GEREÇLER: Ocak 2013 ile Aralýk 2014 tarihleri arasýnda, metastatik pankreas karsinomu tanýsý alan 40 hasta retrospektif olarak incelendi. Hastalarda NLO ile genel saðkalým (OS) ve progresyonsuz saðkalým (PFS) iliþkisi Kaplan-Meier metodu kullanýlarak analiz edildi.
BULGULAR: Çalýþmaya dahil edilen 40 hastanýn ortanca yaþý 58.5 olup, %75 i erkekti. Hastalarýn 21’inde (%52.5) yüksek NLO (≥3.45) saptandý. Nötrofil/lenfosit oraný hem OS hem de PFS için önemli bir prognostik paremetre idi. Ortanca OS NLO yüksek ve normal hastalarda sýrasý ile 2.8 ay ve 11.1 ay (P<0.001) idi. Ortanca PFS ise NLO yüksek ve normal olan hastalarda sýrasý ile 1.6 ay ve 7.9 ay (P<0.001) idi. Ayný zamanda erkek (4.1 ay vs 0.9 ay; P=0.022) ve pankreas baþý yerleþimli tümöre sahip olan (5.8 ay vs 1.3 ay; P=0.046) hastalarda PFS anlamlý olarak daha uzundu.
TARTIÞMA ve SONUÇ: Yüksek NLO, metastatik pankreas kanseri olan hastalarda daha kýsa OS ve PFS' nin bir göstergesidir. Bu sonuçlar daha fazla hasta sayýsý ve diðer prognostik faktörler de dahil edilerek prospektif çalýþmalar ve çok deðiþkenli analiz ile doðrulanmalýdýr.

Anahtar Kelimeler: Pankreas kanser, nötrofil/lenfosit oraný, prognoz

---

CITE